Transaction DateRecipientSharesTypePriceValue
30th October 2020Jonathan Schechter25,000Open or private purchase$0.98$24,442.50
22nd October 2020Jonathan Schechter25,000Open or private purchase$1.10$27,500.00
21st October 2020Jonathan Schechter22,988Open or private purchase$1.10$25,286.80
20th October 2020Jonathan Schechter2,012Open or private purchase$1.10$2,213.20
16th October 2020Joshua Silverman50,000Open or private purchase$1.09$54,445.00
15th October 2020Joshua Silverman50,000Open or private purchase$1.07$53,315.00
28th May 2020Joshua Silverman9,756Grant/award etc.$0.00
1st January 2020Joshua Silverman5,201Exercise of derivative$0.00
27th August 2019Joshua Silverman14,972Payment by withholding$0.78$11,678.16
27th August 2019Joshua Silverman75,950Grant/award etc.$0.00
Neurotrope logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Neurotrope, Inc. engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease.

Ticker: NTRP
Sector: Health Technology
Industry: Medical Specialties
SEC Central Index Key (CIK): 1513856
Employees: 7
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $30 M (0%)
Assets, Current: $31 M (72%)
Property, Plant and Equipment, Net: $25 Th (13%)
Assets: $31 M (72%)
Accounts Payable, Current: $968 Th (134%)
Accrued Liabilities, Current: $100 Th (51%)
Liabilities, Current: $1 M (122%)
Common Stock, Value, Issued: $2 Th (81%)
Common Stock, Shares, Issued: $24 M (81%)
Retained Earnings (Accumulated Deficit): $94 M (6%)
Stockholders' Equity (Parent): $30 M (0%)
Liabilities and Equity: $31 M (72%)
Research and Development: $438 Th (-26%)
General and Administrative Expenses: $2 M (-45%)
Income before taxes: $3 M (-46%)